Gilead signs $1.97bn worth collaboration deal with Arcus Biosciences

As per the terms of the deal, Arcus Biosciences, which is a California-based oncology-focused biopharma company, will get a payment of $375m upon closing from Gilead Sciences. This

The post Gilead signs $1.97bn worth collaboration deal with Arcus Biosciences appeared first on Pharmaceutical Business review.

Bristol Myers Squibb receives EC approval for Zeposia in adults with RRMS with active disease

With the EC marketing authorization, Zeposia, an oral medication taken once daily, becomes the only approved sphingosine-1-phosphate (S1P) receptor modulator for RRMS patients with active disease. The approval

The post Bristol Myers Squibb receives EC approval for Zeposia in adults with RRMS with active disease appeared first on Pharmaceutical Business review.

FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome

If approval is obtained, it would make Nucala the first targeted biologic treatment for patients with this rare and life-threatening disease caused by eosinophilic inflammation. Treatment options are

The post FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome appeared first on Pharmaceutical Business review.

PhaseBio gets FDA nod to begin Covid-19 trial with VIP receptor agonist PB1046

The multi-centre, randomised, double-blind and parallel-group clinical study will evaluate the efficacy and safety of once-weekly subcutaneous injections of PB1046 in hospitalised Covid-19 patients at high risk for

The post PhaseBio gets FDA nod to begin Covid-19 trial with VIP receptor agonist PB1046 appeared first on Pharmaceutical Business review.

FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC

The therapy is approved for patients with squamous or non-squamous disease and regardless of PD-L1 expression. This application was reviewed under the FDA’s Real-Time Oncology Review (RTOR) pilot

The post FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC appeared first on Pharmaceutical Business review.

Merck to acquire Austrian vaccine maker Themis Bioscience

Themis Bioscience is said to have a pipeline of vaccine candidates and immune-modulatory therapies, which have been developed using its measles virus vector platform. In March 2020, the

The post Merck to acquire Austrian vaccine maker Themis Bioscience appeared first on Pharmaceutical Business review.

Shionogi to buy Tetra Therapeutics in $500m deal

The deal value of $500m will be based on the achievement of certain predetermined regulatory and commercial milestones. The transaction will provide Shionogi with global rights to Tetra’s

The post Shionogi to buy Tetra Therapeutics in $500m deal appeared first on Pharmaceutical Business review.

FDA approves Dupixent as first biologic medicine for children aged six to 11 years with moderate-to-severe atopic dermatitis

“This FDA approval is another milestone in the journey for Dupixent as an innovative biologic treatment for atopic dermatitis and other conditions driven in part by type 2

The post FDA approves Dupixent as first biologic medicine for children aged six to 11 years with moderate-to-severe atopic dermatitis appeared first on Pharmaceutical Business review.

US FDA approves Takeda’s ALUNBRIG for rare and serious form of lung cancer

This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations.

The post US FDA approves Takeda’s ALUNBRIG for rare and serious form of lung cancer appeared first on Pharmaceutical Business review.

Novaremed seeks FDA nod for evaluating NRD135S.E1 for treatment of PDPN

In this connection, Novaremed has filed an investigational new drug (IND) application to the FDA. The clinical-stage Swiss biopharma company revealed to have got initial feedback from the

The post Novaremed seeks FDA nod for evaluating NRD135S.E1 for treatment of PDPN appeared first on Pharmaceutical Business review.